Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Universe Pharmaceuticals' Common Equity history spans 5 years, with the latest figure at $45.5 billion for Q3 2024.

  • For Q3 2024, Common Equity rose 62.68% year-over-year to $45.5 billion; the TTM value through Sep 2024 reached $45.5 billion, up 62.68%, while the annual FY2024 figure was $45.5 billion, 62.68% up from the prior year.
  • Common Equity for Q3 2024 was $45.5 billion at Universe Pharmaceuticals, up from $28.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $45.5 billion in Q3 2024 and bottomed at $20.8 million in Q3 2020.
  • The 5-year median for Common Equity is $28.0 billion (2023), against an average of $21.8 billion.
  • The largest annual shift saw Common Equity skyrocketed 75083.64% in 2022 before it fell 20.83% in 2023.
  • A 5-year view of Common Equity shows it stood at $20.8 million in 2020, then surged by 125.89% to $47.0 million in 2021, then surged by 75083.64% to $35.3 billion in 2022, then fell by 20.83% to $28.0 billion in 2023, then soared by 62.68% to $45.5 billion in 2024.
  • Per Business Quant, the three most recent readings for UPC's Common Equity are $45.5 billion (Q3 2024), $28.0 billion (Q3 2023), and $35.3 billion (Q3 2022).